Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,725 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,608 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06897735 | Exploratory Study of Inhaled Afatinib Dimaleate PK Profile(EDDIS-a1) | terminated | Phase 1 | 4 | Petrov, AndreyOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | GenmabINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT06558799 |
| LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)(LUNAR-4) |
| terminated |
| Phase 2 |
| 31 |
| NovoCure GmbHINDUSTRY |
| 7 |
| Jun 1, 2026 |
| clinicaltrials |
| NCT01687647 | Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure(AMORCE-CBP) | terminated | Phase 3 | 463 | University Hospital, CaenOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT03237377 | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | terminated | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | May 27, 2026 | clinicaltrials |
| NCT03520686 | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | terminated | Phase 3 | 102 | ImmunityBio, Inc.INDUSTRY | 1 | May 26, 2026 | clinicaltrials |
| NCT06685718 | A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | terminated | Phase 1 | 33 | BeOne MedicinesINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | terminated | Phase 1 | 154 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | terminated | Phase 2 | 225 | Iovance Biotherapeutics, Inc.INDUSTRY | 7 | May 15, 2026 | clinicaltrials |
| NCT03337698 | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)(Morpheus Lung) | terminated | Phase 1 / Phase 2 | 314 | Hoffmann-La RocheINDUSTRY | 7 | May 12, 2026 | clinicaltrials |
| NCT04746924 | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | terminated | Phase 3 | 669 | BeiGeneINDUSTRY | 19 | May 12, 2026 | clinicaltrials |
| NCT04878952 | Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer | terminated | N/A | 3 | NRG OncologyOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | terminated | Phase 1 | 6 | PfizerINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT03684486 | Rehabilitation by Effort for Patients With Advanced Bronchial Cancer(RehabKBP) | terminated | N/A | 19 | University Hospital, ToulouseOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT01851395 | Rapid Autopsy and Procurement of Cancer Tissue | terminated | — | 32 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT04786093 | Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC | terminated | Phase 2 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05812274 | Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients | terminated | N/A | 30 | Columbia UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | terminated | Phase 1 | 68 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | May 5, 2026 | clinicaltrials |
| NCT05815160 | Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy | terminated | Phase 1 | 34 | Debiopharm International SAINDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT06192004 | Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD(LOOP) | terminated | — | 83 | AstraZenecaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06897579 | Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer | terminated | Phase 2 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06235242 | GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer | terminated | N/A | 2 | Grit BiotechnologyINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06513663 | Exercise as Maintenance Therapy in Advanced Lung Cancer | terminated | N/A | 2 | Indiana UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06519669 | Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer | terminated | N/A | 2 | Grit BiotechnologyINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03737994 | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06491225 | Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma | terminated | Phase 1 | 2 | Grit BiotechnologyINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06974734 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies | terminated | Phase 1 | 8 | PfizerINDUSTRY | 2 | Apr 23, 2026 | clinicaltrials |
| NCT02257619 | Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer | terminated | Phase 2 | 9 | Incyte CorporationINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02298153 | A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma | terminated | Phase 1 | 29 | Incyte CorporationINDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04638582 | Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 6 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | terminated | Phase 1 | 21 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05397093 | ITIL-306 in Advanced Solid Tumors | terminated | Phase 1 | 1 | Instil BioINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02764086 | INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer | terminated | Phase 1 / Phase 2 | 6 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04924192 | A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer | terminated | Phase 2 | 21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04892017 | Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | terminated | Phase 1 | 91 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02679963 | Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer(PIPSeN) | terminated | Phase 2 | 180 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03348748 | Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer | terminated | Early Phase 1 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05765734 | A Study of TAS3351 in NSCLC Patients With EGFRmt(TAS3351) | terminated | Phase 1 | 18 | Taiho Oncology, Inc.INDUSTRY | 5 | Apr 2, 2026 | clinicaltrials |
| NCT06186076 | A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients | terminated | Phase 1 / Phase 2 | 19 | Therapex Co., LtdINDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT04432207 | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer | terminated | Phase 1 | 24 | Imugene LimitedINDUSTRY | 2 | Mar 25, 2026 | clinicaltrials |
| NCT04911166 | Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy | terminated | Phase 1 | 13 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | terminated | Phase 1 | 4 | PfizerINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation(ALAFOSS-01) | terminated | Phase 1 | 17 | AstraZenecaINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT03265496 | Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation(CONCORDE) | terminated | N/A | 21 | Centre Oscar LambretOTHER | 1 | Mar 17, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 3, 2026source: clinicaltrials